jump to navigation

Shire Collaborates on Treatment of Genetic Disorders 11/04/2009

Posted by Morse Barnes-Brown Pendleton in Deal News.
trackback

Shire Human Genetic TherapiesShire, a worldwide leading specialty biopharmaceutical company that focuses on attention deficit and hyperactivity disorder, human genetic therapies and gastrointestinal diseases, has entered into a collaboration and license agreement with Santaris Pharma, another biopharmaceutical company concentrated on improving the treatment and outcome of patients with metabolic disorders and infectious diseases. The two will work to develop RNA-based medicines for the treatment of rare genetic disorders.

MBBP serves as counsel to Shire, and advised it in connection with the structuring, negotiation and documentation of this transaction.

Comments»

No comments yet — be the first.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: